Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice.
Our study examined whether repeated preventive oral administration of live probiotic bacterial strains Escherichia coli O83:K24:H31 (Ec O83), Escherichia coli Nissle 1917 O6:K5:H1 (Ec Nis) and Lactobacillus casei DN 114001 (Lc) can protect mice against dextran sodium sulfate (DSS)-induced colitis. A significant decrease in average symptom score was observed in Ec O83-, Ec Nis- and Lc-pretreated group (p < 0.05). Significant differences in body mass loss between Lc pretreated mice with DSS-induced colitis were found when compared with nontreated mice (p < 0.05). PBS pretreated mice had a significantly shorter colon than Ec O83-, Ec Nis- and Lc-pretreated mice (p < 0.05). Administration of Lc significantly decreased the severity of DSS induced histological marks of inflammation (p < 0.05). A significant difference (p < 0.05) was also found in specific IgA level against given probiotic in enteral fluid between colitic mice and healthy mice pretreated with Ec 083 and Ec Nis.
Kokesová
A
A
Clinic of Pediatric Surgery, University Children Hospital Motol, 150 06 Prague, Czechia.
Frolová
L
L
Kverka
M
M
Sokol
D
D
Rossmann
P
P
Bártová
J
J
Tlaskalová-Hogenová
H
H
D000284:Administration, Oral; D000818:Animals; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D003106:Colon / Q000382:microbiology*; D016264:Dextran Sulfate / Q000009:adverse effects; D004195:Disease Models, Animal; D004926:Escherichia coli; D006651:Histocytochemistry; D007070:Immunoglobulin A / Q000032:analysis; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology*; D007780:Lacticaseibacillus casei; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000494:pharmacology*
D007070:Immunoglobulin A; D016264:Dextran Sulfate